House Appropriations Committee Report Expresses Concerns About FDA; Would Require a Slew of New Action Deadlines By Kurt R. Karst –

read about about a number of concerns at FDA Law Blog.  One specific concern pointed out by the FDA Law Blog is

Compounded Drugs.—The Committee is concerned by the quantity and volume ofrecalls of compounded sterile products and therapies. The Committee awaits the results of a study by GAO providing updated information on state and Federal oversight of compounding. Furthermore, the Committee encourages FDA and the States to work together to improve and strengthen oversight and enforcement of compounding pharmacies.